Cancer Control最新文献

{"title":"Epidemiological Features of Sinonasal Adenocarcinoma and Prognostic Nomogram: A Study Based on the SEER Database.","authors":"Lu Yang, Yufeng Gu, Lei Yu, Qiang Zhou, Li Liu, Ying Mao, Ji Ma, Yong Li, Na Li","doi":"10.1177/10732748241303423","DOIUrl":"10.1177/10732748241303423","url":null,"abstract":"<p><strong>Objective: </strong>Our study aimed to update demographic profiles of sinonasal adenocarcinoma (SNAC) between 2000 and 2020, identify independent prognostic risk factors, and devise a predictive nomogram for overall survival (OS).</p><p><strong>Methods: </strong>Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, cases of SNAC from 2000 to 2020 were analyzed for incidence trends. Univariate and multivariate Cox regression models helped pinpoint factors impacting patient survival. A prognostic nomogram was then created based on these factors and assessed via concordance index, ROC analysis, and calibration curves.</p><p><strong>Results: </strong>Analysis of 488 SNAC patients indicated a rising incidence, peaking among 60-69-year-olds, with a male predominance and the highest occurrence in White populations. Common sites of occurrence included the nasal cavity, and the maxillary and ethmoid sinuses. The nomogram, developed with 184 patients, highlighted older age (≥70), male sex, advanced T stages (T4b, T4a), distant metastasis, larger tumors (≥5 cm), and lack of surgery as poor prognostic indicators. Nomogram performance demonstrated strong predictive capabilities in both training and validation cohorts.</p><p><strong>Conclusion: </strong>This investigation, leveraging the SEER database, elucidates the epidemiology of SNAC and pinpoints key adverse prognostic determinants: age ≥70, male gender, T stages T4b and T4a, presence of distant metastasis, tumor size exceeding 5 cm, and absence of surgical intervention. Moreover, it introduces a novel nomogram capable of accurately forecasting 1-, 3-, and 5-year OS for SNAC patients, thereby enhancing disease comprehension and facilitating the formulation of tailored therapeutic strategies by clinicians.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241303423"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate Artery Embolization in the Setting of Prostate Cancer: Review and Opinion.","authors":"Nainesh Parikh, Kosj Yamoah, Peter Johnstone, Javier Torres-Roca, Julio Pow-Sang, Daniel Fernandez, Anupam Rishi, G Daniel Grass","doi":"10.1177/10732748251317691","DOIUrl":"10.1177/10732748251317691","url":null,"abstract":"<p><p>Prostate Artery Embolization (PAE) is a novel minimally invasive angiographic technique that has been used effectively to treat men with lower urinary tract symptoms (LUTS) from benign prostatic hyperplasia (BPH). However, applications of PAE for men with prostate cancer have been minimally studied. This review serves as an update on the status of PAE in men with prostate cancer, as well as a discussion of emerging indications.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251317691"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Willingness to Implement Narrative Communication Interventions: Mixed Methods Study Among Breast Cancer Patients and Survivors at the University College Hospital, Ibadan, Nigeria.","authors":"Oluwaponmile A Odukoya, Mojisola M Oluwasanu, Ndidi A Okunnuga, Omobolaji Ayandipo, Susan Duncan, Oyedunni S Arulogun, Olufunmilayo I Olopade, Atara Ntekim","doi":"10.1177/10732748251328413","DOIUrl":"10.1177/10732748251328413","url":null,"abstract":"<p><p>PurposeGlobally, black women experience poorer breast cancer outcomes suggesting the need for effective health promotion approaches to increase perceived susceptibility and improve screening practices. Although narrative communication by patients or survivors is increasingly considered an effective approach for better breast cancer outcomes, there is limited information on its use in Nigeria. This study assessed the perception, willingness and generalized self-efficacy of breast cancer patients and survivors at the University College Hospital, Ibadan, to implement narrative communication interventions.Material and MethodsThis was a cross-sectional study, and a mixed-method convergent parallel design was utilized for data collection. Written informed consent was obtained from each study participant for in-depth interviews and a semi-structured questionnaire. Five patients were recruited for in-depth interviews and a semi-structured questionnaire was used to obtain data from 102 patients. Data were analysed using thematic analysis for qualitative data, and descriptive and inferential statistics for quantitative data.ResultsThe mean age of the respondents was 49.3 ± 10.2 years. There was a good perception (97.1%) towards narrative communication interventions. Ninety-eight percent were willing to implement narrative communication interventions and 79.4% had a high generalized self-efficacy. Respondents' educational attainment was significantly associated with the generalized self-efficacy to implement narrative communication intervention programs (<i>P</i> < .05). Most of the in-depth interview participants opined that a pre-diagnosis discussion with a breast cancer patient or survivor would have increased their perceived susceptibility and motivation to screen.ConclusionThis study highlights the potential of breast cancer patients and survivors as breast health educators, sharing their lived experiences to empower and motivate women on prevention and screening. Findings could guide the design of population-level, breast cancer prevention and screening interventions.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251328413"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic Prediction of the Risk of Hepatocellular Carcinoma After DAA Treatment for Hepatitis C Patients.","authors":"Xinyan Ma, Lili Huang, Meijie Yu, Rui Dong, Yifan Wang, Hongbo Chen, Rongbin Yu, Peng Huang, Jie Wang","doi":"10.1177/10732748251316609","DOIUrl":"10.1177/10732748251316609","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this study was to develop and internally validate a hepatocellular carcinoma (HCC) risk prediction model incorporating repeated-measures data (longitudinal model), and compare with baseline predictions.</p><p><strong>Methods: </strong>A total of 1097 participants with chronic hepatitis C after direct-acting antivirals (DAA) treatment were included in this prospective cohort study. The framework of joint models for longitudinal and survival data was used to construct the longitudinal prediction model. For comparison, a baseline model incorporating the same predictors was constructed through the multivariate Cox regression models. Model performance was evaluated using dynamic discrimination index (DDI), areas under the receiver-operating characteristics curves (AUROC), and Brier scores.</p><p><strong>Results: </strong>Over a median follow-up of 7.25 years, 60 patients (5.5%) developed HCC. Key risk factors identified were aspartate aminotransferase (AST), cholinesterase, gamma-glutamyl transferase (GGT), albumin, hemoglobin (Hb), platelet count, alpha-fetoprotein (AFP), antigen-125 (CA-125), and carcinoembryonic antigen (CEA). The final joint model, with GGT and CEA removed, showed superior average predictive performance (DDI = .871) compared to models with all predictors included. Validation showed high predictive accuracy for HCC, with AUROCs above .9 for 1-, 3-, 4-, and 5-year predictions. In comparison, the baseline Cox model only achieved mediocre AUROCs of .7 (.75, .67, .69, and .67, respectively).</p><p><strong>Conclusion: </strong>Compared to static models, our dynamic prediction model can predict the risk of HCC in patients after DAA treatment more accurately, providing better information to distinguish high-risk populations.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251316609"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11831632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Explainable Machine Learning Models for Colorectal Cancer Prediction Using Clinical Laboratory Data.","authors":"Rui Li, Xiaoyan Hao, Yanjun Diao, Liu Yang, Jiayun Liu","doi":"10.1177/10732748251336417","DOIUrl":"https://doi.org/10.1177/10732748251336417","url":null,"abstract":"<p><p>IntroductionEarly diagnosis of colorectal cancer (CRC) poses a significant clinical challenge. This study aims to develop machine learning (ML) models for CRC risk prediction using clinical laboratory data.MethodsThis retrospective, single-center study analyzed laboratory examination data from healthy controls (HC), polyp patients (Polyp), and CRC patients between 2013 and 2023. Five ML algorithms, including adaptive boosting (AdaBoost), extreme gradient boosting (XGBoost), decision tree (DT), logistic regression (LR), and random forest (RF), were employed to classify subjects into HC vs Polyp vs CRC, HC vs CRC, and Polyp vs CRC, respectively.ResultsThis study included 31 539 subjects: 11 793 HCs, 10 125 polyp patients, and 9621 CRC patients. The XGBoost model achieved the highest AUCs of 0.966 for differentiating HC from CRC and 0.881 for Polyp from CRC, outperforming carcino-embryonic antigen (CEA) and fecal occult blood testing (FOBT) tests. This model could also identify CEA-negative or FOBT-negative CRC patients. Incorporating stool miR-92a detection into the model further improved diagnostic performance. Shapley additive explanations (SHAP) plots indicated that FOBT, CEA, lymphocyte percentage (LYMPH%), and hematocrit (HCT) were the most significant features contributing to CRC diagnosis. Additionally, a computational tool for predicting CRC risk based on the optimal model was developed, designed for researchers with programming experience.ConclusionFive ML models for CRC diagnosis, based on ten routine laboratory test items, were developed, achieving higher diagnostic accuracies than traditional CRC biomarkers. The diagnostic capabilities of these ML models can be further enhanced by including stool miR-92a levels.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251336417"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Awareness of Contraindications Among Cancer Patients in Riyadh, Saudi Arabia: A Cross-Sectional Study.","authors":"Mansour Almuqbil, Rama Abdulhamid Mohammed Alobaid, Amouna Abdulrahim Mazal Alhamad, Noor Hussam Eddin, Nora Al Yahya, Walaa F Alsanie, Abdulhakeem S Alamri, Majid Alhomrani, Amal F Alshammary, Rafiulla Gilkaramenthi, Syed Mohammed Basheeruddin Asdaq","doi":"10.1177/10732748251313498","DOIUrl":"10.1177/10732748251313498","url":null,"abstract":"<p><strong>Introduction: </strong>Cancer patients often face challenges in managing their disease, particularly with regard to contraindications related to medications, foods, and physical activity, which can negatively affect treatment outcomes. This study aimed to evaluate cancer patients' awareness of these contraindications and to explore the influence of sociodemographic factors, support systems, comorbidities, and medication use on their knowledge.</p><p><strong>Methods: </strong>A cross-sectional prospective study was conducted with 125 cancer patients in Saudi Arabia between December 2022 and February 2023. Participants were selected using purposive sampling, and data were collected through a validated questionnaire. Multinomial regression analysis was employed to identify the predictors of awareness of contraindicated medications, foods, and other environmental factors.</p><p><strong>Results: </strong>Nationality, co-morbidities, and cancer duration were significant predictors of awareness regarding contraindicated drugs. Saudi patients were more likely to be aware of contraindicated medications (<i>P</i> = 0.010), and those without chronic diseases were 15 times more likely to know about drug contraindications (OR = 15.076, 95% CI: 3.442-66.042). Cancer diagnosis (<i>P</i> = 0.033) and cancer duration (<i>P</i> = 0.022) were also significant for food contraindications. Over 58% were unaware of the need to regulate body temperature during treatment. Location influenced exercise awareness (<i>P</i> = 0.064) and complementary and alternative medicine (CAM) awareness, with rural participants showing higher CAM knowledge (<i>P</i> = 0.001).</p><p><strong>Conclusion: </strong>This study emphasizes the need to improve cancer patients' awareness of contraindications, particularly regarding medications and foods. Key factors influencing awareness include nationality, co-morbidities, and cancer duration. While family support is beneficial, it doesn't directly enhance knowledge, highlighting the importance of targeted educational interventions to improve patient outcomes and safety.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251313498"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742164/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Age-Based Nomogram as the Best Predictor for Long-Term Overall Survival in Head and Neck Mucosa-Associated Lymphoid Tissue Lymphoma.","authors":"Chaoxin Fan, Aimin Jiang, Rui Zhao, Miaomiao Chen","doi":"10.1177/10732748251321661","DOIUrl":"10.1177/10732748251321661","url":null,"abstract":"<p><strong>Objectives: </strong>Head and neck mucosa-associated lymphoid tissue (MALT) lymphoma, a rare subtype of non-Hodgkin lymphoma, has received limited attention regarding its prognosis. This study aimed to illuminate the clinical characteristics and identify prognostic factors for head and neck MALT lymphoma, intending to develop an accessible tool for clinicians to predict long-term survival probabilities and inform therapeutic strategies.</p><p><strong>Methods: </strong>This multicentre retrospective study enrolled 424 head and neck MALT lymphoma patients from the Surveillance, Epidemiology, and End Results Program (SEER) database. Least absolute shrinkage and selection operator (LASSO)-Cox regression analysis identified independent prognostic factors for overall survival (OS), leading to the development of an age-based nomogram predicting OS probabilities at 5, 10, and 15 years. Evaluation included time-dependent receiver operating curve (ROC), calibration curves, and decision curve analysis.</p><p><strong>Results: </strong>Multivariate Cox analysis highlighted age exceeding 65 years [hazards ratio (HR): 2.97, 95% confidence interval (CI): 1.94-4.57; <i>P</i> < 0.001] and unmarried status (HR: 1.58, 95% CI: 1.07-2.33, <i>P</i> = 0.023) as significantly associated with shorter OS, while black race correlated with longer OS (HR: 0.25, 95% CI: 0.09-0.69, <i>P</i> = 0.007). The age-based nomogram, integrating these factors, demonstrated efficacy in predicting 5-year [area under the curve (AUC): 0.640] and 10-year OS (AUC: 0.705), with an impressive AUC of 0.842 for the 15-year OS probability in the training cohort. Decision curve analysis affirmed the nomogram's clinical utility, surpassing individual factors. Consistent results were observed in validation cohorts.</p><p><strong>Conclusion: </strong>Our study provides crucial insights into head and neck MALT lymphoma, filling gaps in understanding its clinical landscape. The validated age-based nomogram serves as a practical tool for clinicians, offering enhanced prognostic precision and guiding personalized treatment strategies in this understudied lymphoma subtype.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251321661"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Clinical Outcomes in Patients With HER2+ Metastatic Breast Cancer Receiving Tucatinib-Based Therapy After 2 or More Prior Metastatic HER2-Directed Regimens.","authors":"Carey Anders, Edward Neuberger, Karen Bartley, Brian T Pittner, Amadou Sow, Shu Wang, Peter A Kaufman","doi":"10.1177/10732748251327711","DOIUrl":"https://doi.org/10.1177/10732748251327711","url":null,"abstract":"<p><p><b>Introduction:</b> Tucatinib is an oral human epidermal growth factor receptor 2 (HER2)-targeted therapy approved by the European Medicines Agency (EMA) for use in combination with trastuzumab and capecitabine for patients with HER2 + locally advanced or metastatic breast cancer (MBC) treated with ≥2 prior HER2-directed regimens. This real-world study describes patient characteristics and clinical outcomes with tucatinib after receiving ≥2 HER2-targeted therapies in the metastatic setting.<b>Methods:</b> This study included patients diagnosed with HER2 + MBC (between January 2017 and December 2022) who received tucatinib after ≥2 HER2-directed therapies in the metastatic setting in a US-based nationwide, de-identified electronic health record-derived MBC database. Patient demographic and clinical characteristics were captured at baseline (before tucatinib initiation). Outcomes assessed were real-world time to treatment discontinuation (rwTTD), real-world time to next treatment (rwTTNT), real-world overall survival (rwOS), and treatment persistence.<b>Results:</b> Of 3449 patients with HER2 + MBC, 89 received tucatinib, of which 30 received prior trastuzumab deruxtecan (T-DXd). Median (range) age of patients was 57 (30-84) years, 60.7% were White, and 66.3% had Eastern Cooperative Oncology Group performance status ≤1. Median (95% confidence interval) rwTTD was 5.9 (5.0-9.4) months, rwTTNT was 8.4 (6.2-11.8) months, and rwOS was 24.9 (15.6-not reached [NR]) months; in the post-T-DXd subgroup, these results were 6.4 (3.6-11.6), 6.4 (4.5-11.9), and 12.6 (11.9-NR) months. Treatment persistence was 43.9% (overall) and 33.3% (post-T-DXd) at 12 months and 15.4% at 24 months (overall).<b>Conclusion:</b> Tucatinib administered after ≥2 HER2-targeted therapies in the metastatic setting is an effective treatment option in patients with HER2 + MBC, including those treated with prior T-DXd.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251327711"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Biomarkers for Hepatocellular Carcinoma Patients Treated With Atezolizumab plus Bevacizumab Combination Therapy.","authors":"Long-Bin Jeng, Horng-Ren Yang, Chiao-Fang Teng","doi":"10.1177/10732748251339243","DOIUrl":"https://doi.org/10.1177/10732748251339243","url":null,"abstract":"<p><p><b>Background:</b> Despite the significant progress in prevention and therapy, hepatocellular carcinoma (HCC) is still one of the most prevalent and lethal human cancers worldwide. <b>Purpose:</b> Recently, the combination of atezolizumab (an immune checkpoint inhibitor, anti-programmed death ligand 1 antibody) and bevacizumab (an antiangiogenic agent, anti-vascular endothelial growth factor antibody) has emerged as a new and effective first-line systemic therapy in the treatment of patients with unresectable HCC. However, the development of prognostic biomarkers for the early identification and timely intervention of HCC patients with poor prognosis after atezolizumab plus bevacizumab combination therapy remains a key goal to achieve better patient survival.<b>Research Design:</b> This review provides a comprehensive summary of the evidence in the literature validating a single or a combination of biomarker(s) in various sampling sources at diverse time points with prognostic value in predicting the outcomes of HCC patients receiving atezolizumab plus bevacizumab combination therapy. A plethora of promising prognostic biomarkers is identified here, and further studies to implement these biomarkers in clinical practices are urgently needed.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251339243"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China.","authors":"Chang Liu, Tao Li, Xiaoran Cui, Yahui Lv, Min Liu, Xin Zhou, Fan Yang, Yi Dong, Ruixin Li, Fan Zhang, Tong Zhang, Yi Hu","doi":"10.1177/10732748251347572","DOIUrl":"10.1177/10732748251347572","url":null,"abstract":"<p><p>HER2-mutated non-small lung cancer (NSCLC) in China represents a substantial patient population characterized by an unfavorable prognosis. However, at present, the main clinical treatment options are relatively limited. HER2 mutations in Chinese NSCLC (2019-2024) demonstrated 3.8%-5.6% prevalence via NGS, exceeding global baselines, with superior detection vs PCR (4.5% vs 3.1%). In addition, more attention was paid to molecular analysis and the detection rate of HER2 genomic alterations in NSCLC patients in eastern and northern China compared to other parts of China, which might be related to regional economic differences and geographic differences in lung cancer epidemiology. The evolving therapeutic landscape has established new-generation TKIs (pyrotinib) and antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (T-Dxd) as targeted strategies for HER2-mutant NSCLC. Despite late research initiation, China rapidly advanced from retrospective analyses to pioneering new drug trials. In general, the incidence of HER2-mutated NSCLC in the Chinese population seems to be higher than the world average, and there is a large number of missed HER2-mutated NSCLC patients in China. In this field, ADCs and novel TKIs are being developed and researched in spurts, and new drugs are moving from back-line therapy to front-line therapy, and from single-drug regimens to combination regimens.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251347572"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}